-
- Company Brochure is available in PDF.
- CSR Report is available in PDF.
To scroll text in this page
Global Navigation end
Updated Information
-
February 15, 2010
- Posted Presentation Slides for Conference Hosted by Citi.
-
February 10, 2010
- Updated "Message from CEO" section.
-
February 02, 2010
- Posted Financial Results for 3Q/FY2009
-
February 02, 2010
- Updated "IR Calendar" Section
-
January 29, 2010
- Theravance Inc. announced that it received a letter indicating that Theravance's response to the Complete Response letter for the injectable antibiotic telavancin for the treatment of nosocomial pneumonia is incomplete.
-
January 18, 2010
- Updated "Message from CEO" section.
-
January 13, 2010
- Posted Presentation Slides for Mizuho Investment Conference
-
January 07, 2010
- Updated "Stock Information" Section
-
December 15, 2009
- Updated "Shareholder Return" sections
-
December 01, 2009
- Theravance Inc. announced that EMEA has completed the validation phase for the telavancin MAA for the treatment of nosocomial pneumonia and complicated skin and soft tissue infections.
-
November 30, 2009
- Theravance Inc. announced that it received complete response letter from the FDA for the injectable antibiotic telavancin for the treatment of nosocominal pneumonia.
-
November 10, 2009
- Updated "Financial Highlights" Section
-
November 06, 2009
- Posted Presentation Slides for Information Meeting for 2Q/ FY2009 Results
-
November 05, 2009
- Updated "Shareholder Return" Section
-
November 05, 2009
- Updated "Current Share Status" Section
-
November 05, 2009
- Posted Financial Results for 2Q/FY2009
-
September 30, 2009
- Posted Presentation Slides for Conference Hosted by Deutsche Securities
-
September 29, 2009
- Posted Presentation Slides for Information Meeting Focused on Drug Discovery Research
-
September 09, 2009
- Annual Report 2009
-
September 07, 2009
- Updated "Message from CEO" section
Main Text end
Local Navigation end
